Want to see COO full AI Analyst Report?
Operating Income by Segment
Illustrates profitability across various business segments, indicating which areas are most efficient and where there may be room for improvement or strategic focus.CooperVision is clearly the earnings engine — operating income has risen steadily into 2026, reflecting product momentum and operating leverage — while CooperSurgical’s results are volatile and collapse in Apr‑2026 due to the large litigation accrual (the $271.6M net settlement excluded from non‑GAAP), which masks underlying fertility and diagnostics strength amid a strategic review. Corporate remains a steady drag. Treat the GAAP litigation hit as largely one‑off, but watch APAC softness, near‑term margin headwinds and strategic‑review execution for real value realization.
Date | CooperVision | CooperSurgical | Corporate |
|---|---|---|---|
Jul 31, 2026 | $205.50M | $41.10M | -$24.60M |
Apr 30, 2026 | $215.60M | -$225.00M | -$21.60M |
Jan 31, 2026 | $210.20M | $26.80M | -$24.20M |
Oct 31, 2025 | $156.70M | $3.70M | -$20.00M |
Jul 31, 2025 | $202.60M | -$4.20M | -$22.70M |
Apr 30, 2025 | $186.40M | $23.70M | -$25.30M |
Jan 31, 2025 | $183.90M | $20.20M | -$22.10M |
Oct 31, 2024 | $188.50M | $31.40M | -$21.50M |
Jul 31, 2024 | $172.70M | $41.30M | -$21.50M |
Apr 30, 2024 | $160.20M | $21.60M | -$20.10M |